Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p62
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 62/66)
Character Range: 205290–208807

is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16148  P16148  CN16148  Fluconazole                  Cryptococcal meningitis                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures - Streamlined Authority Code 16148
                                                      The treatment must be maintenance therapy; AND
                                                      Patient must be immunosuppressed; AND
                                                      Patient must be unable to take a solid dose form of fluconazole; AND
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.

[411] Schedule 4, Part 2, omit entry for Variation Code "V10745"
[412] Schedule 4, Part 2, omit entry for Variation Code "V10747"
[413] Schedule 4, Part 2, omit entry for Variation Code "V10751"
[414] Schedule 4, Part 2, after entry for Variation Code "V15457"
insert:
V15457  Nivolumab  An increase in repeat prescriptions, up to a value of 11, may only be sought where the prescribed dosing is 240 mg administered fortnightly.

[415] Schedule 4, Part 2, omit second entry for Variation Code "V15818"
[416] Schedule 4, Part 2, after entry for Variation Code "V15832"
insert:
V15994  Fentanyl   Authorities for increased maximum quantities and/or repeats must only be considered for chronic severe disabling pain where the total duration of non-PBS and PBS opioid analgesic treatment: (i) exceeds 12 months and the palliative care patient is unable to have annual pain management review due to their clinical condition; or (ii) exceeds 12 months and the patient's clinical need for continuing opioid treatment has been confirmed through consultation with the patient by another medical practitioner or a palliative care nurse practitioner in the past 12 months; or (iii) has exceeded 12 months prior to 1 June 2020 and the patient's clinical need for continuing opioid treatment has not been confirmed through consultation with the patient by another medical practitioner or a palliative care nurse practitioner in the past 12 months, but is planned in the next 3 months.
        Methadone  Authority requests extending treatment duration up to 1 month may be requested through the Online PBS Authorities system or by calling Services Australia.
                   Authority requests extending treatment duration beyond 1 month may be requested through the Online PBS Authorities system or in writing and must not provide a treatment duration exceeding 3 months (quantity sufficient for up to 1 month treatment and sufficient repeats).
V15996  Fentanyl   Authorities for increased maximum quantities and/or repeats under this restriction must only be considered for chronic severe disabling pain where the total